Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
June 10, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
June 03, 2021 08:30 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
May 26, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
May 17, 2021 16:01 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
May 10, 2021 10:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
May 10, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

And Provides Interim Clinical Data Update Partial response data demonstrates activity of CUE-101 as monotherapy in patient with human papilloma virus positive recurrent/metastatic head and neck...
May 06, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference

CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
March 16, 2021 16:01 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma...
March 15, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...